Anteris to Present at September Healthcare Investor Conferences
Rhea-AI Summary
Anteris Technologies Global Corp. (NASDAQ/ASX: AVR) announced that Vice Chairman and CEO Wayne Paterson will present at three September 2026 U.S. healthcare investor conferences: the Cantor Global Healthcare Conference in New York, the Wells Fargo 21st Annual Healthcare Conference in Boston, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York.
Each event will feature a fireside chat and 1x1 investor meetings at scheduled times between September 9 and 14, 2026.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 11 | 2Q26 earnings | Positive | -3.3% | Reported Q2 cash outflows and R&D spending while advancing PARADIGM enrollment. |
| Jun 08 | French regulatory clearance | Positive | -3.1% | Received French clearance enabling recruitment for the global pivotal PARADIGM trial. |
| May 13 | Board appointments | Neutral | -2.5% | Added two directors as the DurAVR program advanced toward potential licensure. |
| May 12 | 1Q26 earnings | Positive | -2.5% | Reported capital raises, cash outflows, enrollment progress and new clinical data. |
| May 05 | U.S. trial initiation | Positive | +1.0% | Announced first U.S. PARADIGM patients were enrolled and treated at Montefiore Medical Center. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of five recent news events had negative 24-hour reactions, including regulatory clearance and clinical-progress announcements.
Key Terms
transcatheter heart valve medical
aortic stenosis medical
balloon-expandable technical
biomimetic valve medical
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference.
The details of each conference are as follows:
Cantor Global Healthcare Conference
| Date: | Wednesday, September 9, 2026 (US time) |
| Format: | Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings |
| Time: | 11:30AM (US EST) |
| Room: | Track 1 – Metropolitan Room |
| Location: | Waldorf Astoria Hotel, New York |
Wells Fargo Healthcare Conference
| Date: | Thursday, September 10, 2026 (US time) |
| Format: | Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings |
| Time: | 9:30AM (US EST) |
| Room: | Track 1 – Picasso 6 |
| Location: | Encore Boston Harbor Hotel, Boston |
Morgan Stanley Healthcare Conference
| Date: | Monday, September 14, 2026 (US time) |
| Format: | Fireside chat with Morgan Stanley Healthcare Team |
| Time: | 9:15AM (US EST) |
| Room: | Soho Complex 7th Floor |
| Location: | Sheraton Times Square Hotel, New York |
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Actual future events may vary from these forward-looking statements and readers are cautioned not to put undue reliance on forward-looking statements. Other than as required by law, Anteris gives no representation or guarantee that the occurrence of any of the events or circumstances expressed or implied in these statements will occur. In addition, except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
| Global Investor Relations investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200 | Investor Relations (US) mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269 | |
| Website X | www.anteristech.com @AnterisTech https://www.linkedin.com/company/anteristech | |
